# BullFrog AI Holdings, Inc.: financial statements, quarterly

BFRG · Nasdaq · CIK 1829247 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bfrg.md) · [Financials](/companies/bfrg/financials.md) · [Filings](/companies/bfrg/filings.md) · [Insiders](/companies/bfrg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bfrg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [65.0](/filings/0001493152-24-044329.md) | [0.0 d](/filings/0001493152-25-010367.md) | not reported | not reported | not reported | not reported | not reported | [33.3](/filings/0001628280-26-057121.md) | [83.4](/filings/0001493152-25-023496.md) | [0.0 d](/filings/0001493152-26-011644.md) | not reported | [215](/filings/0001628280-26-057121.md) |
| Cost of revenue | $k | [5.2](/filings/0001493152-24-044329.md) | [0.0 d](/filings/0001493152-25-010367.md) | not reported | not reported | not reported | not reported | not reported | [26.7](/filings/0001628280-26-057121.md) | [68.0](/filings/0001493152-25-023496.md) | [0.0 d](/filings/0001493152-26-011644.md) | not reported | [108](/filings/0001628280-26-057121.md) |
| Gross profit | $k | [59.8](/filings/0001493152-24-044329.md) | [0.0 d](/filings/0001493152-25-010367.md) | not reported | not reported | not reported | not reported | not reported | [6.5](/filings/0001628280-26-057121.md) | [15.4](/filings/0001493152-25-023496.md) | [0.0 d](/filings/0001493152-26-011644.md) | not reported | [107](/filings/0001628280-26-057121.md) |
| Research and development | $k | [380](/filings/0001493152-24-044329.md) | [409 d](/filings/0001493152-25-010367.md) | [552](/filings/0001641172-25-009946.md) | [514](/filings/0001641172-25-023560.md) | [567](/filings/0001493152-25-023496.md) | [591 d](/filings/0001493152-26-011644.md) | [576](/filings/0001493152-26-023068.md) | [480](/filings/0001628280-26-057121.md) | [346](/filings/0001493152-25-023496.md) | [397 d](/filings/0001493152-26-011644.md) | [435](/filings/0001493152-26-023068.md) | [339](/filings/0001628280-26-057121.md) |
| Operating income | $k | [(1,304)](/filings/0001493152-24-044329.md) | [(1,336) d](/filings/0001493152-25-010367.md) | [(1,966)](/filings/0001641172-25-009946.md) | [(1,682)](/filings/0001641172-25-023560.md) | [(1,820)](/filings/0001493152-25-023496.md) | [(1,769) d](/filings/0001493152-26-011644.md) | [(2,057)](/filings/0001493152-26-023068.md) | [(1,470)](/filings/0001628280-26-057121.md) | [(1,570)](/filings/0001493152-25-023496.md) | [(1,499) d](/filings/0001493152-26-011644.md) | [(1,615)](/filings/0001493152-26-023068.md) | [(1,419)](/filings/0001628280-26-057121.md) |
| Interest expense | $k | [5.8](/filings/0001493152-23-041125.md) | [2.2 d](/filings/0001493152-24-011964.md) | [3.3](/filings/0001493152-24-018633.md) | [7.9](/filings/0001641172-25-023560.md) | [5.0](/filings/0001493152-25-023496.md) | [2.0 d](/filings/0001493152-26-011644.md) | [1.0](/filings/0001493152-26-023068.md) | [2.4](/filings/0001628280-26-057121.md) | [1.5](/filings/0001493152-25-023496.md) | [0.6 d](/filings/0001493152-26-011644.md) | [1.0](/filings/0001493152-26-023068.md) | [2.4](/filings/0001628280-26-057121.md) |
| Net income | $k | [(1,253)](/filings/0001493152-24-044329.md) | [(1,297) d](/filings/0001493152-25-010367.md) | [(1,904)](/filings/0001493152-25-023496.md) | [(1,612)](/filings/0001493152-25-023496.md) | [(1,763)](/filings/0001493152-25-023496.md) | [(1,715) d](/filings/0001493152-26-011644.md) | [(2,018)](/filings/0001628280-26-057121.md) | [(1,449)](/filings/0001628280-26-057121.md) | [(1,552)](/filings/0001493152-25-023496.md) | [(1,480) d](/filings/0001493152-26-011644.md) | [(1,593)](/filings/0001628280-26-057121.md) | [(1,372)](/filings/0001628280-26-057121.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0001493152-24-044329.md) | not reported | [(0.26)](/filings/0001641172-25-009946.md) | [(0.20)](/filings/0001641172-25-023560.md) | [(0.22)](/filings/0001493152-25-023496.md) | not reported | [(0.21)](/filings/0001493152-26-023068.md) | [(0.15)](/filings/0001628280-26-057121.md) | [(0.15)](/filings/0001493152-25-023496.md) | not reported | [(0.12)](/filings/0001493152-26-023068.md) | [(0.07)](/filings/0001628280-26-057121.md) |
| Basic EPS | $ per share | [(0.21)](/filings/0001493152-24-044329.md) | not reported | [(0.26)](/filings/0001641172-25-009946.md) | [(0.20)](/filings/0001641172-25-023560.md) | [(0.22)](/filings/0001493152-25-023496.md) | not reported | [(0.21)](/filings/0001493152-26-023068.md) | [(0.15)](/filings/0001628280-26-057121.md) | [(0.15)](/filings/0001493152-25-023496.md) | not reported | [(0.12)](/filings/0001493152-26-023068.md) | [(0.07)](/filings/0001628280-26-057121.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [3,856](/filings/0001493152-23-041125.md) | [2,625](/filings/0001493152-25-010367.md) | [7,011](/filings/0001493152-24-018633.md) | [5,614](/filings/0001493152-24-030553.md) | [4,239](/filings/0001493152-24-044329.md) | [5,436](/filings/0001493152-26-011644.md) | [3,802](/filings/0001641172-25-009946.md) | [2,474](/filings/0001641172-25-023560.md) | [1,991](/filings/0001493152-25-023496.md) | [2,184](/filings/0001628280-26-057121.md) | [5,080](/filings/0001493152-26-023068.md) | [6,918](/filings/0001628280-26-057121.md) |
| Current assets | $k | [4,208](/filings/0001493152-23-041125.md) | [2,771](/filings/0001493152-25-010367.md) | [7,643](/filings/0001493152-24-018633.md) | [6,071](/filings/0001493152-24-030553.md) | [4,598](/filings/0001493152-24-044329.md) | [5,548](/filings/0001493152-26-011644.md) | [4,082](/filings/0001641172-25-009946.md) | [2,702](/filings/0001641172-25-023560.md) | [2,536](/filings/0001493152-25-023496.md) | [2,584](/filings/0001628280-26-057121.md) | [5,315](/filings/0001493152-26-023068.md) | [7,471](/filings/0001628280-26-057121.md) |
| Total assets | $k | [4,215](/filings/0001493152-23-041125.md) | [2,777](/filings/0001493152-25-010367.md) | [7,649](/filings/0001493152-24-018633.md) | [6,077](/filings/0001493152-24-030553.md) | [4,602](/filings/0001493152-24-044329.md) | [5,552](/filings/0001493152-26-011644.md) | [4,086](/filings/0001641172-25-009946.md) | [2,869](/filings/0001641172-25-023560.md) | [2,702](/filings/0001493152-25-023496.md) | [2,808](/filings/0001628280-26-057121.md) | [5,539](/filings/0001493152-26-023068.md) | [7,694](/filings/0001628280-26-057121.md) |
| Current liabilities | $k | [446](/filings/0001493152-23-041125.md) | [184](/filings/0001493152-25-010367.md) | [845](/filings/0001493152-24-018633.md) | [691](/filings/0001493152-24-030553.md) | [779](/filings/0001493152-24-044329.md) | [588](/filings/0001493152-26-011644.md) | [839](/filings/0001641172-25-009946.md) | [681](/filings/0001641172-25-023560.md) | [759](/filings/0001493152-25-023496.md) | [672](/filings/0001628280-26-057121.md) | [652](/filings/0001493152-26-023068.md) | [707](/filings/0001628280-26-057121.md) |
| Total liabilities | $k | not reported | [184](/filings/0001493152-25-010367.md) | [845](/filings/0001493152-24-018633.md) | [691](/filings/0001493152-24-030553.md) | [779](/filings/0001493152-24-044329.md) | [588](/filings/0001493152-26-011644.md) | [839](/filings/0001641172-25-009946.md) | [681](/filings/0001641172-25-023560.md) | [759](/filings/0001493152-25-023496.md) | [672](/filings/0001628280-26-057121.md) | [652](/filings/0001493152-26-023068.md) | [707](/filings/0001628280-26-057121.md) |
| Short-term borrowings | $k | [213](/filings/0001493152-23-041125.md) | not reported | [507](/filings/0001493152-24-018633.md) | [341](/filings/0001493152-24-030553.md) | [172](/filings/0001493152-24-044329.md) | not reported | [164](/filings/0001641172-25-009946.md) | [110](/filings/0001641172-25-023560.md) | [55.6](/filings/0001493152-25-023496.md) | not reported | not reported | not reported |
| Shareholders' equity | $k | [3,769](/filings/0001493152-24-044329.md) | [2,592](/filings/0001493152-26-011644.md) | [6,804](/filings/0001493152-25-023496.md) | [5,385](/filings/0001493152-25-023496.md) | [3,823](/filings/0001493152-25-023496.md) | [4,964](/filings/0001628280-26-057121.md) | [3,246](/filings/0001628280-26-057121.md) | [2,188](/filings/0001628280-26-057121.md) | [1,944](/filings/0001493152-25-023496.md) | [2,136](/filings/0001628280-26-057121.md) | [4,887](/filings/0001628280-26-057121.md) | [6,987](/filings/0001628280-26-057121.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,394) d](/filings/0001493152-24-044329.md) | [(1,018) d](/filings/0001493152-25-010367.md) | [(1,902)](/filings/0001641172-25-009946.md) | [(1,231) d](/filings/0001641172-25-023560.md) | [(1,206) d](/filings/0001493152-25-023496.md) | [(1,272) d](/filings/0001493152-26-011644.md) | [(1,798)](/filings/0001493152-26-023068.md) | [(1,432) d](/filings/0001628280-26-057121.md) | [(1,107) d](/filings/0001493152-25-023496.md) | [(1,185) d](/filings/0001493152-26-011644.md) | [(1,694)](/filings/0001493152-26-023068.md) | [(1,513) d](/filings/0001628280-26-057121.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [4.8](/filings/0001493152-23-041125.md) | [4.8](/filings/0001493152-24-018633.md) | [6.1](/filings/0001493152-24-030553.md) | [6.1](/filings/0001493152-24-044329.md) | [7.4](/filings/0001641172-25-009946.md) | [8.1](/filings/0001641172-25-023560.md) | [8.1](/filings/0001493152-25-023496.md) | [9.7](/filings/0001493152-26-023068.md) | [9.7](/filings/0001628280-26-057121.md) | [10.4](/filings/0001493152-25-023496.md) | [12.9](/filings/0001493152-26-023068.md) | [18.8](/filings/0001628280-26-057121.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 18,541,651 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001628280-26-057121.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.